Jao K - Search Results

1

Descriptive analysis of durvalumab use in unresectable stage III non-small cell lung cancer in patients treated in Quebec's University teaching hospitals.

Labrie V, Lefebvre J, Labbé C, Jao K, Malick M, Simard S, Bouchard N. Labrie V, et al. Among authors: jao k. Front Oncol. 2024 Dec 12;14:1506172. doi: 10.3389/fonc.2024.1506172. eCollection 2024. Front Oncol. 2024. PMID: 39726712 Free PMC article.

2

Ready or not? Lung cancer diagnosis in 2015.

Jao K, Labbe C, Leighl NB. Jao K, et al. Curr Oncol. 2015 Aug;22(4):239-42. doi: 10.3747/co.22.2647. Curr Oncol. 2015. PMID: 26300660 Free PMC article. No abstract available.

3

Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.

Tomasini P, Walia P, Labbe C, Jao K, Leighl NB. Tomasini P, et al. Among authors: jao k. Oncologist. 2016 Dec;21(12):1450-1460. doi: 10.1634/theoncologist.2015-0084. Epub 2016 Nov 2. Oncologist. 2016. PMID: 27807303 Free PMC article. Review.

4

Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).

Labbé C, Cabanero M, Korpanty GJ, Tomasini P, Doherty MK, Mascaux C, Jao K, Pitcher B, Wang R, Pintilie M, Leighl NB, Feld R, Liu G, Bradbury PA, Kamel-Reid S, Tsao MS, Shepherd FA. Labbé C, et al. Among authors: jao k. Lung Cancer. 2017 Sep;111:23-29. doi: 10.1016/j.lungcan.2017.06.014. Epub 2017 Jun 24. Lung Cancer. 2017. PMID: 28838393

5

Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer.

Doherty MK, Korpanty GJ, Tomasini P, Alizadeh M, Jao K, Labbé C, Mascaux CM, Martin P, Kamel-Reid S, Tsao MS, Pintilie M, Liu G, Bradbury PA, Feld R, Leighl NB, Chung C, Shepherd FA. Doherty MK, et al. Among authors: jao k. Radiother Oncol. 2017 May;123(2):195-202. doi: 10.1016/j.radonc.2017.03.007. Epub 2017 Mar 28. Radiother Oncol. 2017. PMID: 28363487

6

Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer.

Tomasini P, Mascaux C, Jao K, Labbe C, Kamel-Reid S, Stockley T, Hwang DM, Leighl NB, Liu G, Bradbury PA, Pintilie M, Tsao MS, Shepherd FA. Tomasini P, et al. Among authors: jao k. Clin Lung Cancer. 2019 May;20(3):e338-e345. doi: 10.1016/j.cllc.2018.12.009. Epub 2018 Dec 19. Clin Lung Cancer. 2019. PMID: 30770327

7

Diffuse Hemorrhagic Brain Metastases in an ALK Fusion Positive Patient on Crizotinib.

Jao K, Tomasini P, Labbe C, Doherty M, Shepherd FA. Jao K, et al. J Thorac Oncol. 2015 Jun;10(6):965-6. doi: 10.1097/JTO.0000000000000403. J Thorac Oncol. 2015. PMID: 26001146 Free article. No abstract available.

8

The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.

Jao K, Tomasini P, Kamel-Reid S, Korpanty GJ, Mascaux C, Sakashita S, Labbé C, Leighl NB, Liu G, Feld R, Bradbury PA, Hwang DM, Pintilie M, Tsao MS, Shepherd FA. Jao K, et al. Lung Cancer. 2018 Sep;123:22-29. doi: 10.1016/j.lungcan.2018.06.023. Epub 2018 Jun 19. Lung Cancer. 2018. PMID: 30089591

9

Challenges of Immunotherapy in Stage IV Non-Small-Cell Lung Cancer.

Stock-Martineau S, Magner K, Jao K, Wheatley-Price P. Stock-Martineau S, et al. Among authors: jao k. JCO Oncol Pract. 2021 Aug;17(8):465-471. doi: 10.1200/OP.20.00949. Epub 2021 Mar 15. JCO Oncol Pract. 2021. PMID: 33720756 Review.

10

A Canadian Perspective on the Challenges for Delivery of Curative-Intent Therapy in Stage III Unresectable Non-Small Cell Lung Cancer.

Brade A, Jao K, Yu S, Cheema P, Doucette S, Christofides A, Schellenberg D. Brade A, et al. Among authors: jao k. Curr Oncol. 2021 Apr 24;28(3):1618-1629. doi: 10.3390/curroncol28030151. Curr Oncol. 2021. PMID: 33923355 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

28 results

Search Page

Filters